Allurion Technologies

ALUR · NYSE

$0.475−$0.46 (−49.20%)TodayMarket closed · Oct 20, 2:36 PM ET

No price history for this range.

Latest news

Press releaseJun 17, 4:05 PM ETBusiness Wire
Allurion Advances Plan to Re-List
Press releaseJun 2, 9:00 AM ETBusiness Wire
Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum
NewsMar 3, 7:05 AM ET
8 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session
Press releaseMar 2, 9:00 AM ETBusiness Wire
Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
NewsFeb 25, 10:39 AM ETNabaparna Bhattacharya
What's Going On With Allurion Stock On Wednesday?
NewsFeb 24, 4:06 PM ET
12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session
NewsFeb 24, 12:38 PM ETAvi Kapoor
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views
NewsFeb 24, 9:50 AM ETAvi Kapoor
Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings
Press releaseFeb 24, 9:15 AM ETBusiness Wire
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
NewsFeb 23, 1:36 PM ETAvi Kapoor
Dow Tumbles Over 700 Points; Dominion Energy Posts Upbeat Earnings
NewsFeb 23, 9:50 AM ETAvi Kapoor
US Stocks Mixed; Domino's Pizza Shares Gain After Q4 Earnings
Press releaseFeb 23, 9:00 AM ETBusiness Wire
Allurion Receives U.S. FDA Approval
NewsFeb 4, 7:05 AM ET
12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Press releaseFeb 3, 9:00 AM ETBusiness Wire
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
Press releaseJan 12, 8:30 AM ETBusiness Wire
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
NewsDec 3, 7:05 AM ET
12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 25, 9:25 AM ETBusiness Wire
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
Press releaseNov 20, 9:00 AM ETBusiness Wire
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
Press releaseNov 18, 9:00 AM ETBusiness Wire
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Press releaseNov 12, 8:00 AM ETBusiness Wire
Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
NewsNov 11, 2:04 PM ET
A Look at Allurion Technologies's Upcoming Earnings Report
NewsNov 11, 12:09 PM ET
12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
Press releaseNov 11, 8:45 AM ETBusiness Wire
Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing
Press releaseNov 6, 4:05 PM ETBusiness Wire
Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025
Press releaseOct 7, 8:00 AM ETBusiness Wire
Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss
Press releaseSep 30, 4:05 PM ETBusiness Wire
Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
NewsAug 26, 5:08 PM ET
12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session
NewsAug 20, 1:06 PM ET
12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
Press releaseAug 13, 8:00 AM ETBusiness Wire
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update
Press releaseAug 7, 4:05 PM ETBusiness Wire
Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025
Press releaseAug 5, 8:00 AM ETBusiness Wire
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
Press releaseJul 22, 8:00 AM ETBusiness Wire
Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program
Press releaseMar 26, 8:00 AM ETBusiness Wire
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Press releaseNov 13, 8:00 AM ETBusiness Wire
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
Press releaseAug 13, 8:00 AM ETBusiness Wire
Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Allurion Advances Plan to Re-List

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

8 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

What's Going On With Allurion Stock On Wednesday?

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views

Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Dow Tumbles Over 700 Points; Dominion Energy Posts Upbeat Earnings

US Stocks Mixed; Domino's Pizza Shares Gain After Q4 Earnings

Allurion Receives U.S. FDA Approval

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 12, 2025

A Look at Allurion Technologies's Upcoming Earnings Report

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update